TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07766499: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Assess the Efficacy and Safety of THB335 in Adult Participants With Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic

Sponsor: Calixis Inc. · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 81 pts

Competing Trials Overlap

9 Active Trials

Excess Burn Exposure

$6,042,400

Rescue Site Savings

+$3,984,000

Unlock Full NCT07766499 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07766499 Rescue Dossier →